|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Neurosurgery (Drs. Mikuni, Takayama, Satow, Yamada, Hayashi, Nishida, Taki, Enatsu, Miyamoto, and Hashimoto) and Neurology (Ikeda), Kyoto University Graduate School of Medicine, Kyoto, Japan.
Address correspondence and reprint requests to Dr. Nobuhiro Mikuni, Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 6068507, Japan; e-mail: mikunin{at}kuhp.kyoto-u.ac.jp
The authors evaluated adverse effects of intracarotid propofol injection during a Wada test and their risk factors in 58 patients. Nineteen patients had an adverse effect, mostly in patients receiving more than 10 mg. For patients older than age 55 years or those requiring an injection dose greater than 20 mg to produce hemiplegia, propofol should be injected slowly and patients monitored for excitatory movements.
Editorial, see page 1692
See also page 1723
This article was previously published in electronic format as an Expedited E-Pub on September 7, 2005, at www.neurology.org.
Supported by Grants-in-Aid for Scientific Research (C2) 14571310 from the Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT).
Disclosure: The authors report no conflicts of interest.
Received March 31, 2005. Accepted in final form June 22, 2005.
This article has been cited by other articles:
![]() |
N. Lao, H. Nie, L. X. Xu, L. Z. Xiong, H. Zhang, Y. Y. Fan, and B. R. Wang Efficacy of intracarotid propofol infusion and impact of cerebral blood flow alteration Br. J. Anaesth., December 9, 2008; (2008) aen346v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Grote and K. Meador Has amobarbital expired?: Considering the future of the Wada Neurology, December 13, 2005; 65(11): 1692 - 1693. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |